Biocause Pharma(SZ:000627) Zheng Quan Zhi Xing·2025-07-14 16:23Group 1 - The company is unable to disclose the 2024 annual report and the 2025 first quarter report within the legal deadline, leading to a trading suspension since May 6, 2025 [1][2] - The stock will be subject to delisting risk warning upon resumption of trading on July 8, 2025, if the company fails to disclose the required reports within two months of the delisting risk warning [2][3] - The company has received a notice of investigation from the China Securities Regulatory Commission (CSRC) for failing to disclose periodic reports on time, which may lead to further regulatory actions [1][3] Group 2 - The company is required to issue risk warning announcements at least every five trading days during the delisting risk warning period [2] - This announcement marks the first risk warning regarding potential mandatory delisting due to non-compliance with disclosure requirements [2] - The company is currently working to complete the necessary reports and improve communication with relevant parties to expedite the disclosure process [2]